Is Emideltide (DSIP) legal in the US?

Approved vs compoundable vs “research-use” — the distinction that matters

An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 Emideltide was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.

What happened on July 24

The FDA’s Pharmacy Compounding Advisory Committee heard the evidence and voted against adding Emideltide to the 503A list for opioid withdrawal, chronic insomnia and narcolepsy — the only one of the seven substances the committee declined to recommend. The FDA is not bound by that vote, but it has opened no rulemaking here, and the current status is unchanged: off Category 2, not on Category 1, and not authorized for compounding.

An approved narcolepsy drug changes the argument

On 5 August 2026, twelve days after the committee declined to recommend Emideltide, the FDA approved Orzeyful (oveporexton) tablets for narcolepsy type 1 in adults. It is the first medicine approved for that disorder as a whole rather than for individual symptoms, and the first to act on the loss of orexin signalling that causes it.

That matters here because of how compounding is justified. A 503A pharmacy compounds when no suitable approved product serves the patient. Narcolepsy was one of the three indications the nominators put forward for Emideltide. For that indication an approved, mechanism-targeted alternative now exists, and the clinical-need case is weaker than it was in July.

Two smaller points are worth keeping. The approved drug is a small molecule that imitates a neuropeptide rather than a peptide itself — peptides taken by mouth are generally destroyed in the gut, which is why the product that worked is not one. And it has been recommended for scheduling under the Controlled Substances Act, while Emideltide is not scheduled at all. Being unscheduled is not the same as being lawful to sell for human use. How US peptide regulation actually works →

Primary sources: FDA 503A interim list; FDA-reviewed uses per PCAC agenda · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895 · FDA press release of 5 August 2026 approving Orzeyful (oveporexton) for narcolepsy type 1 · Controlled Substances Act schedules.